Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Brown TA, Byrd K, Vreeland TJ, Clifton GT, Jackson DO, Hale DF, Herbert GS, Myers JW, Greene JM, Berry JS, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwel GL, Peoples GE.
Brown TA, et al. Among authors: herbert gs.
Cancer Med. 2019 Aug;8(10):4678-4687. doi: 10.1002/cam4.2378. Epub 2019 Jul 5.
Cancer Med. 2019.
PMID: 31274231
Free PMC article.
Clinical Trial.